Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD
- PMID: 28196649
- PMCID: PMC5526715
- DOI: 10.1053/j.ajkd.2016.11.018
Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD
Abstract
Background: Diabetes is the leading cause of end-stage renal disease (ESRD) and a significant contributor to mortality in the general population. We examined the associations of hemoglobin A1c (HbA1c) levels with ESRD and death in a population with diabetes and chronic kidney disease (CKD).
Study design: Cohort study.
Setting & participants: 6,165 patients with diabetes (treated with oral hypoglycemic agents and/or insulin) and CKD stages 1 to 5 at a large health care system.
Predictor: HbA1c level (examined as a categorical and continuous measure).
Outcomes: All-cause and cause-specific mortality ascertained from the Ohio Department of Health mortality files and ESRD ascertained from the US Renal Data System.
Results: During a median 2.3 years of follow-up, 957 patients died (887 pre-ESRD deaths) and 205 patients reached ESRD. In a Cox proportional hazards model, after multivariable adjustment including for kidney function, HbA1c level < 6% was associated with higher risk for death when compared with HbA1c levels of 6% to 6.9% (HR, 1.23; 95% CI, 1.01-1.50). Similarly, HbA1c level ≥ 9% was associated with higher risk for all-cause death (HR, 1.34; 95% CI, 1.06-1.69). In competing-risk models, baseline HbA1c level was not associated with ESRD. For cause-specific mortality, diabetes accounted for >12% of deaths overall and >19% of deaths among those with HbA1c levels > 9%.
Limitations: Small proportion of participants with advanced kidney disease; single-center population.
Conclusions: In this cohort of patients with CKD with diabetes, HbA1c levels < 6% and ≥9% were associated with higher risk for death. HbA1c levels were not associated with ESRD in this specific CKD population. Diabetes-related deaths increased with higher HbA1c levels.
Keywords: Glycated hemoglobin; HbA(1c); chronic kidney disease (CKD); death and kidney disease; diabetes control; diabetes mellitus; diabetic nephropathy; end stage renal disease (ESRD); incident ESRD; mortality.
Copyright © 2017 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Financial Disclosure
Dr Navaneethan has served as consultant for Bayer and Boeringher-Ingelheim. The other authors declare that they have no relevant financial interests.
Figures
Similar articles
-
Glycated Albumin and Adverse Clinical Outcomes in Patients With CKD: A Prospective Cohort Study.Am J Kidney Dis. 2024 Sep;84(3):329-338. doi: 10.1053/j.ajkd.2024.02.006. Epub 2024 Mar 20. Am J Kidney Dis. 2024. PMID: 38518919
-
The association of glycated hemoglobin with mortality and ESKD among persons with diabetes and chronic kidney disease.J Diabetes Complications. 2019 Apr;33(4):296-301. doi: 10.1016/j.jdiacomp.2018.12.010. Epub 2019 Jan 7. J Diabetes Complications. 2019. PMID: 30795915 Free PMC article.
-
Incident Type 2 Diabetes Among Individuals With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.Am J Kidney Dis. 2019 Jan;73(1):72-81. doi: 10.1053/j.ajkd.2018.06.017. Epub 2018 Sep 1. Am J Kidney Dis. 2019. PMID: 30177484 Free PMC article.
-
Kidney Disease in Diabetes.In: Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M, Fradkin JE, editors. Diabetes in America. 3rd edition. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018 Aug. CHAPTER 22. In: Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M, Fradkin JE, editors. Diabetes in America. 3rd edition. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018 Aug. CHAPTER 22. PMID: 33651560 Free Books & Documents. Review.
-
Glycated albumin in diabetic patients with chronic kidney disease.Clin Chim Acta. 2012 Oct 9;413(19-20):1555-61. doi: 10.1016/j.cca.2012.04.025. Epub 2012 May 10. Clin Chim Acta. 2012. PMID: 22579765 Review.
Cited by
-
Systemic immune inflammation index and all-cause mortality in chronic kidney disease: A prospective cohort study.Immun Inflamm Dis. 2024 Sep;12(9):e1358. doi: 10.1002/iid3.1358. Immun Inflamm Dis. 2024. PMID: 39254488 Free PMC article.
-
What is the best predictor of mortality in patients with type 2 diabetes and chronic kidney disease: mean, variability of HbA1c or HbA1c-Hemoglobin ratio?BMC Nephrol. 2024 Jul 31;25(1):246. doi: 10.1186/s12882-024-03686-9. BMC Nephrol. 2024. PMID: 39085774 Free PMC article.
-
Patient Characteristics and Outcomes of Hospitalized Chronic Kidney Disease Patients with and without Type 2 Diabetes Mellitus: Observations from the German Claims Data-Based Cohort of the CaReMe-CKD Multinational Study.Clin Epidemiol. 2024 Jul 22;16:487-500. doi: 10.2147/CLEP.S459767. eCollection 2024. Clin Epidemiol. 2024. PMID: 39070102 Free PMC article.
-
MicroRNA-630 alleviates inflammatory reactions in rats with diabetic kidney disease by targeting toll-like receptor 4.World J Diabetes. 2024 Mar 15;15(3):488-501. doi: 10.4239/wjd.v15.i3.488. World J Diabetes. 2024. PMID: 38591087 Free PMC article.
-
Glycated Albumin and Adverse Clinical Outcomes in Patients With CKD: A Prospective Cohort Study.Am J Kidney Dis. 2024 Sep;84(3):329-338. doi: 10.1053/j.ajkd.2024.02.006. Epub 2024 Mar 20. Am J Kidney Dis. 2024. PMID: 38518919
References
-
- Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–234. - PubMed
-
- Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380(9844):807–814. - PubMed
-
- USRDS. Incidence, prevalence, patient characteristics, and treatment modalities. 2016;2016(08/04)
-
- Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
